Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.
classical Hodgkin lymphoma
older patients
population‐based
survival
treatment
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
16
03
2021
revised:
09
04
2021
accepted:
10
04
2021
entrez:
18
7
2022
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (
Identifiants
pubmed: 35844675
doi: 10.1002/jha2.202
pii: JHA2202
pmc: PMC9175745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
400-412Informations de copyright
© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Daniel Molin has received honoraria from Roche, Merck, Bristol‐Myers Squibb and Takeda. Björn Engelbrekt Wahlin has received research funding from Roche and Gilead, and he has been a consultant for Roche and Gilead. Lotta Hansson has received research grant support from Gilead and Janssen‐Cilag and honoraria from Abbvie. Ingrid Glimelius has received honoraria from Janssen‐Cilag. Marzia Palma has received research grant support from Beigene and Takeda. None of the other authors have any relevant conflict of interest to disclose.
Références
Ann Oncol. 2014 Aug;25(8):1622-8
pubmed: 24827123
Blood. 2012 Jan 19;119(3):692-5
pubmed: 22117038
Ann Oncol. 2005 Jan;16(1):124-31
pubmed: 15598949
J Intern Med. 2006 Aug;260(2):103-17
pubmed: 16882274
Blood. 2016 May 5;127(18):2189-92
pubmed: 26834240
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Br J Haematol. 2021 Apr;193(1):63-71
pubmed: 32926420
Br J Haematol. 2013 Apr;161(1):76-86
pubmed: 23356491
Ann Oncol. 1991 Apr;2(4):297-302
pubmed: 1714293
Blood. 2012 Jan 26;119(4):990-6
pubmed: 22147892
Ann Oncol. 2010 Oct;21(10):2045-2051
pubmed: 20423912
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Eur J Haematol. 2018 Jul;101(1):106-114
pubmed: 29727497
Br J Haematol. 2002 Nov;119(2):432-40
pubmed: 12406082
Int J Cancer. 2013 Aug 1;133(3):687-94
pubmed: 23335127
Leuk Lymphoma. 2007 Mar;48(3):570-6
pubmed: 17454601
Lancet. 2012 May 12;379(9828):1791-9
pubmed: 22480758
J Fluency Disord. 2002 Winter;27(4):269-87; quiz 287-8
pubmed: 12506446
Cancer. 1995 Nov 15;76(10):1687-8
pubmed: 8625034
Blood. 2008 Mar 15;111(6):2977-83
pubmed: 18096762
J Clin Oncol. 2005 Dec 20;23(36):9208-18
pubmed: 16314615
Acta Oncol. 2009;48(1):27-33
pubmed: 18767000
Biostatistics. 2009 Jan;10(1):136-46
pubmed: 18599516
J Clin Oncol. 2009 Sep 20;27(27):4548-54
pubmed: 19704068
Crit Rev Oncol Hematol. 2009 Sep;71(3):222-32
pubmed: 19179093
Br J Haematol. 2017 May;177(3):449-456
pubmed: 28233899
Lancet. 2015 Apr 11;385(9976):1418-27
pubmed: 25539730
Ann Hematol. 2016 Apr;95(5):809-16
pubmed: 26878861
Br J Haematol. 2015 Jul;170(2):179-84
pubmed: 25891777
Am J Hematol. 2015 Dec;90(12):1128-34
pubmed: 26349012
Br J Haematol. 2014 Mar;164(6):851-7
pubmed: 24433418
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
J Clin Oncol. 2016 Jun 10;34(17):2028-36
pubmed: 27114593
Eur J Haematol. 2014 Nov;93(5):392-9
pubmed: 24797378
J Clin Oncol. 2009 Feb 10;27(5):805-11
pubmed: 19124807
Blood. 2012 Jun 21;119(25):6005-15
pubmed: 22577177
Leukemia. 2015 Mar;29(3):668-76
pubmed: 25151959